Role of PI3K in the Progression and Regression of Atherosclerosis

Phosphatidylinositol 3 kinase (PI3K) is a key molecule in the initiation of signal transduction pathways after the binding of extracellular signals to cell surface receptors. An intracellular kinase, PI3K activates multiple intracellular signaling pathways that affect cell growth, proliferation, mig...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 632378
Main Authors Zhao, Yunyun, Qian, Yongjiang, Sun, Zhen, Shen, Xinyi, Cai, Yaoyao, Li, Lihua, Wang, Zhongqun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.03.2021
Subjects
atherosclerosis
drug therapy
Pharmacology
PI3K
plaque
signaling pathways
atherosclerosis
plaque
drug therapy
signaling pathways
PI3K
Online AccessGet full text

Cover

More Information
Summary:Phosphatidylinositol 3 kinase (PI3K) is a key molecule in the initiation of signal transduction pathways after the binding of extracellular signals to cell surface receptors. An intracellular kinase, PI3K activates multiple intracellular signaling pathways that affect cell growth, proliferation, migration, secretion, differentiation, transcription and translation. Dysregulation of PI3K activity, and as aberrant PI3K signaling, lead to a broad range of human diseases, such as cancer, immune disorders, diabetes, and cardiovascular diseases. A growing number of studies have shown that PI3K and its signaling pathways play key roles in the pathophysiological process of atherosclerosis. Furthermore, drugs targeting PI3K and its related signaling pathways are promising treatments for atherosclerosis. Therefore, we have reviewed how PI3K, an important regulatory factor, mediates the development of atherosclerosis and how targeting PI3K can be used to prevent and treat atherosclerosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Xinjiang Cai, UCLA David Geffen School of Medicine, Los Angeles, United States
InKyeom Kim, Kyungpook National University, South Korea
Edited by: Liberato Berrino, University of Campania Luigi Vanvitelli, Italy
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.632378